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E-mail address: Paul.Cairns@fccc.edu (P. Cairns).Cancer is a disease initiated and driven by the accumulation and interplay of genetic and epigenetic
mutations of genes involved in the regulation of cell growth and signaling. Dysregulation of these
genes and pathways in a cell leads to a growth advantage and clonal expansion. The epigenetic alter-
ations involved in the initiation and progression of cancer are DNA methylation and histone mod-
iﬁcations which interact to remodel chromatin, as well as RNA interference. These alterations can be
used as candidate targets in molecular tests for risk, early detection, prognosis, prediction of
response to therapy, and monitoring, as well as new therapeutic targets in cancer. In this review,
we discuss the rationale, studies to date, and issues in the translational application of epigenetics
using epithelial ovarian cancer as a speciﬁc example of all types of cancer.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction MicroRNAs (miRNA) are short non-coding RNA sequences thatThe three main epigenetic mechanisms are DNA methylation
and histone modiﬁcations as well as RNA interference. DNA meth-
ylation involves the chemical modiﬁcation of cytosoine by the
addition of a methyl group to the 50 carbon of the cytosine base
in CG dinucleotides. Compared to normal cells, cancer cells show
global hypomethylation mainly of repetitive elements in the DNA
sequence but also localized hypermethylation. In particular, CpG
islands in the promoter regions of certain genes can be hyperme-
thylated with associated loss of expression [1].
Histone modiﬁcations act together with DNA methylation at
promoters to organize chromatin and thereby regulate gene
expression. Histone complexes consist of two subunits each of
the H2A, H2B, H3 and H4 histones forming an octamer that wraps
146 bps of DNA-referred to as a nucleosome. The H1 linker histone
binds to the outside of the nucleosome and seals two turns of DNA.
The nucleosome allows for large quantities of DNA to be packaged
into a small area. Histone tails remain external to the core and are
the substrate of modiﬁcation. As a result, how the histone tail mod-
iﬁcations interact with DNA can inﬂuence chromatin condensation,
stability and structure. Modiﬁcations to the histone core compo-
nents as well as the histone linker have been demonstrated as cru-
cial in the regulation of different cellular processes [2–4].
Alterations in the status of histone modiﬁcations are evident in tu-
mor cells [1].chemical Societies. Published by Eregulate gene expression through targeted degradation of mRNA
transcripts [5]. The alterations in gene expression that result from
miRNA-initiated destruction have signiﬁcant impact on cell func-
tion and survival. Atypical expression of miRNAs has been demon-
strated in cancer cells and is known to be involved in
tumorigenesis. To date, almost a thousandmiRNAs have been iden-
tiﬁed in human cells. MiRNAs are the result of several processing
events. Initially, primary transcripts, known as pri-miRNAs, are
transcribed and cleaved by the enzyme Drosha into a 60–70 nucle-
otide sequence that forms a stem loop structure. These pri-miRNAs
are then cleaved to short sequences (about 21–25 nucleotides in
length) called pre-miRNAs by the enzyme Dicer. These sequences
are then associated with RISC (RNA induced silencing complex)
to initiate mRNA degradation. The expression levels of certain
miRNAs have been shown be altered in tumor cells compared to
the normal progenitor cells [6–8].
Epigenetic alterations present in neoplastic cells are potential
molecular tools to detect and manage cancer. Epithelial ovarian
cancer is a disease that is neither common nor rare, has no speciﬁc
symptoms and is mostly detected at an advanced stage, and sooner
or later resistant to chemotherapy [9]. Here, we use epithelial ovar-
ian cancer as an example to discuss the epigenetic alterations and
their translational application to risk, detection, prognosis, predic-
tion of response, and therapy for cancer.
2. Risk of developing cancer
The identiﬁcation of individuals at a higher risk of devel-
oping a particular cancer might allow lifestyle intervention,lsevier B.V. All rights reserved.
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of ovarian cancer is not well understood but known modulators
of risk include a woman’s reproductive history and increasing
age. Pregnancy at a younger age as well as number of pregnancies,
oral contraceptive use, tubal ligation and hysterectomy have all
been associated with a lower risk of ovarian cancer [10]. To begin
to examine if epigenetics underlies this protective effect, it is nec-
essary to have a deﬁnitive identiﬁcation of the normal progenitor
cells from which epithelial ovarian cancer develops. A consensus
on the origin of ovarian tumors has not yet been formed. Normal
human ovarian surface epithelial (OSE) cells have been most
widely used in laboratory studies. More recently, inclusion cysts
or cells from the ﬁmbria of the fallopian tube that implant in the
ovary have been proposed as progenitors. A mullerian origin for
ovarian tumor cells has also been argued for [10–13].
A related barrier to the study of the role of epigenetic altera-
tions in risk is the inability to access the ovaries, fallopian tubes
or peritoneum in a non-invasive manner in order to obtain speci-
mens from women at progressive age cohorts whom subsequently
develop ovarian cancer and women whom never develop ovarian
cancer. Few prophylactic oophorectomies from high-risk women
and even fewer from average-risk women with benign disease
show clear evidence of early ovarian cancer. Some other anatomi-
cal sites are more amenable to sampling for risk e.g., oral cancer by
simple visual examination and bladder cancer from urothelial cells
shed in a simple urine specimen. To overcome this issue, animal
studies in which environmental factors or carcinogens are admin-
istered over time followed by ovariectomy and analysis of the epi-
genome may be considered.
These two issues of deﬁnitive identiﬁcation of the normal pro-
genitor cells and non-invasive access to those cells at a time point
before diagnosis of cancer apply to some other cancer types and
need to be overcome before exploratory studies of global methyl-
ation, histone modiﬁcations and miRNA expression proﬁles can
be performed. Peripheral blood lymphocytes have been suggested
as surrogate cells for the study of environmentally-induced altera-
tions in cancer. The biological rationale for lymphocytes over nor-
mal progenitor cells of epithelial cancer is not compelling and is
likely made partly to circumvent the issue of invasive access and
also because lymphocytes have been banked in large population
studies and are therefore available to researchers. Since it is known
that epigenetic alterations can occur in premalignant lesions or the
earliest identiﬁed stages of neoplasia of many epithelial cancers
[14,15], these alterations are candidate targets for chemopreven-
tion. There is some pre-clinical evidence for prevention by epige-
netic drugs in animal models of neoplasia [16–19].3. Early detection
3.1. Diagnosis of ovarian cancer
Detection of cancer at an early stage generally correlates with
good prognosis and higher survival rates. Ovarian cancer is diag-
nosed by a physical exam, computerized tomography (CT) scan,
ultrasound, and the CA-125 serum marker. All these methods have
been limited in success for early detection. Regular pelvic exams
miss early stage tumors and the speciﬁcity of ultrasonography
for ovarian cancer is limited by detection of cysts and solid benign
lesions. Serum levels of CA-125 are elevated in only approximately
80% of ovarian cancer patients and lack speciﬁcity. CA-125 is ele-
vated in other types of cancer, can be present in women with be-
nign ovarian conditions and in up to 0.5–1% of the normal
population. Therefore this blood test cannot be used alone to diag-
nose ovarian cancer. Exploratory surgery (laparoscopy) is often
necessary to diagnose epithelial ovarian cancer, since ovarianmasses may also be caused by benign cysts, other primary ovarian
cancers such as germ cell or stromal cell, or by metastasis to the
ovaries [20].
3.2. Nucleic acid based detection of cancer in body ﬂuids
Alterations at the DNA or RNA level are promising markers for
molecular diagnosis and prognosis because they can precede obvi-
ous cancer, are highly speciﬁc, can be detected by PCR-based tech-
niques at extremely sensitive levels, and can provide diagnostic
and prognostic information simultaneously. Nucleic acid-based
markers have been found in body ﬂuids that surround or drain
from the organ of interest [21,22]. Women at high risk, i.e., familial
ovarian, BRCA1, BRCA2 and hereditary non-polyposis colorectal
cancer (HNPCC) carriers, may be willing to undergo a semi-inva-
sive peritoneal needle or catheter wash for early diagnosis. How-
ever, serum is a readily available, non-invasive ﬂuid that contains
circulating tumor cells and/or free tumor DNA and could poten-
tially be used for early detection in both high risk and sporadic
ovarian cancer [23] (Fig. 1A).
3.3. Aberrant promoter hypermethylation in blood
Aberrant DNA hypermethylation of CpG islands in the promoter
region of genes is well established as a commonmechanism for the
silencing of tumor suppressor genes in cancer cells and serves as an
alternative mechanism to point mutation or deletion for functional
inactivation [24]. The classical tumor suppressor genes BRCA1,
p16INK4a and mutL homolog1 (MLH1) as well as the putative tumor
suppressor genes RAS association domain family protein 1A (RASSF1A)
and opioid binding protein/cell adhesion molecule like (OPCML)
among others have been identiﬁed as hypermethylatedwith associ-
ated loss of expression in ovarian cancer [25–32]. The availability of
a commonand early alteration, such as promoter hypermethylation,
to target the presence of cancer combined with the availability of
technology, e.g., methylation speciﬁc PCR (MSP), which is capable
of the detection of few methylated alleles from neoplastic cells in
a background of many unmethylated alleles from normal or
non-neoplastic cells, led to studies of the feasibility of methylation-
based detection of cancer in body ﬂuids or biopsies [33].
An initial study obtained matched tumor, pre-operative serum
or plasma, and peritoneal ﬂuid (washes or ascites) DNAs from 50
patients with epithelial ovarian tumors. Microdissected tissue
DNA and body ﬂuid DNA was analyzed by conventional gel-based
MSP for hypermethylation status of the normally unmethylated
BRCA1 and RASSF1A, adenomatous polyposis coli (APC), p14ARF,
p16INK4a or death associated protein-kinase (DAP-Kinase) tumor sup-
pressor genes. Hypermethylation of one or more of the gene panel
was found in all 50 tumor DNAs (100% diagnostic coverage) and in
all histological cell types, grades and stages of epithelial ovarian tu-
mor examined. An identical pattern of gene hypermethylation was
found in the matched pre-operative serum DNA from 41 of 50 pa-
tients (82% sensitivity) including all 8 cases of stage I disease.
Hypermethylation was detected in 27 of 29 peritoneal ﬂuid DNAs
from stage Ic-IV patients, including 3 cases with negative or atyp-
ical cytology. In contrast, no hypermethylation was observed,
albeit in a relatively small number of controls that included
non-neoplastic tissue, peritoneal ﬂuid or serum from age-matched
women with no evidence of ovarian cancer [23].
3.4. Histone modiﬁcations and miRNA expression for early detection
The western, immunohistochemistry (IHC), and chromatin
immunoprecipitation (ChIP) assays currently used to examine his-
tone modiﬁcations are generally not amenable to the detection of
alterations from few tumor cells in a mixture of predominantly
Fig. 1. Translational applications of epigenetic alterations in cancer.
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mor cell-rich tissue specimens obtained at time of surgical resec-
tion and therefore, at present, histone modiﬁcations seem more
relevant as markers for prognosis and prediction.
The demonstration that miRNA expression proﬁles are different
in many types of cancer compared to the normal progenitor cells
suggests that a neoplastic cell-speciﬁc proﬁle could be used for
detection and prognosis [6–8]. Furthermore, there is evidence that
miRNAs are more stable and/or more resistant to RNase activity
than are mRNAs in tissue and body ﬂuid specimens thereby facili-
tating analysis [6,34–36].
A study of ovarian patients prior to chemotherapy found 8 miR-
NAs with dysregulated expression in patient sera compared to nor-
mal controls [37]. The dysregulated miRNAs included miR-29a,
miR-93 and miR-155 previously reported to be dysregulated in pri-
mary ovarian tumors [7,37–39]. Another study examining the miR-
NA proﬁles in 5 ml of blood of 24 patients with recurrence of
ovarian cancer (mostly of serous histology) found 147miRNAs dys-
regulated in the ovarian cancer compared to normal control blood
specimens [40]. The list included miR-16, miR-29a, miR-106b and
miR-155 also previously shown to be dysregulated in ovarian can-
cer [7,37–39].
The precursor genomic sequence of some microRNAs are lo-
cated in CpG islands that can be methylated [41–43]. Such methyl-
ation, if aberrant in neoplastic cells, is another potential target for
molecular detection.
3.5. Issues of epigenetic alterations in early detection
There are several barriers to the validation of gene methylation
for early detection of ovarian cancer. To examine the speciﬁcity of
an alteration for cancer, it is useful to determine if a gene is meth-
ylated only in neoplastic cells. It is therefore important to examine
normal progenitor cell DNA to see if a gene is imprinted, has tissue
speciﬁc methylation or shows age-related methylation. As well as
the question of origin of ovarian tumors, there is the further prob-
lem of obtaining sufﬁcient cells from a surgical specimen for
molecular analysis. A brushing of OSE cells from normal ovary or
microdissection of ﬁmbria, do not contain sufﬁcient numbers of
cells to permit more than minimal molecular analysis. SV40-
immortalized human OSE cell lines do provide sufﬁcient amounts
of DNA to examine gene methylation however while these cell
lines may be non-tumorigenic they cannot be considered biologi-
cally normal. Similarly, the amount of DNA in 1 ml of serum limitsanalysis. For retrospective validation, curators of large serum spec-
imen banks are reluctant to release 1 ml of serum for study of a nu-
cleic acid marker when proteomic studies typically require far less
specimen. Prospective collection of serum would allow sufﬁcient
amounts for molecular studies, for example several ml may be dis-
carded at time of a CA-125 test, but this requires time to accrue
large numbers of samples and so has proved a delay to validation.
By deﬁnition, a circulating body ﬂuid can be accessed by many
different anatomical sites. The use of serum means differential
diagnosis of the organ site from which the positive methylation re-
sult originated is needed. To date, few genes have demonstrated
speciﬁcity of aberrant hypermethylation to a single cell type or
anatomical site. One example is BRCA1 hypermethylation which
is restricted to ovarian and breast tumors. Another is GSTP1 meth-
ylated in breast tumors but rarely, if ever, in ovarian cancer [28]. It
is possible that genes that show hypermethylation speciﬁc to epi-
thelial ovarian cancer remain to be discovered. Several such genes
included in a panel with BRCA1 and GSTP1 might allow develop-
ment of an algorithm sufﬁciently accurate for differential diagnosis
of ovarian cancer. In the near term an epigenetic marker would
likely be used alongside CA-125 to improve the accuracy of
CA-125 screening. Arguments against screening the general popu-
lation for the >90% of ovarian cancer that is sporadic include that
there are no or minimal risk factors, a false positive can mean an
unnecessary laparotomy, and that the disease is relatively uncom-
mon [20]. It may be that current cost beneﬁt analysis would only
allow screening in the general population if ovarian cancer was
‘bundled’’ with screening for other more common cancers. This
would place further importance on differential diagnosis.
Alterations in miRNA expression would appear to be a more
abundant target for early detection strategies in body ﬂuids as each
tumor cell contains hundreds or thousands of molecules of a par-
ticular miRNA but only one to several (in aneuploid cells) methyl-
ated alleles of a gene. That initial miRNA studies used several ml of
serum/plasma would question such abundance and suggest similar
issues to limiting amounts of DNA [34,44–46]. The ratio of few tu-
mor cells to many normal cells in blood is another issue depending
on the relative difference in miRNA expression between normal
and tumor cells.
It has been stated that miRNAs are stable i.e., resistant to degra-
dation through secondary structure and/or being contained in exo-
somes [47]. While miRNA is more stable than mRNA, in a clinical
specimen miRNA should survive no better or worse than short
pieces of degraded DNA currently used in forensics and archeology.
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[48]. Overall it seems that miRNA will have the same practical is-
sues as DNA methylation as a target for early detection.
Many other methylated tumor suppressor and cancer genes as
well as individual miRNAs important in ovarian tumorigenesis
likely remain to be identiﬁed. Most useful for early detection are
genes with aberrant methylation or microRNAs with aberrant
expression that is early and frequent in tumorigenesis, neoplastic
cell-speciﬁc, organ type-speciﬁc, biologically relevant, capable of
providing simultaneous diagnostic and prognostic information,
and amenable to technology that can detect the gene methylation
or miRNA expression at a sensitive level in a non-invasive speci-
men with sufﬁcient lead time for effective treatment, at an accept-
able ﬁnancial cost.4. Prognosis
4.1. Prognostic or predictive marker
A prognostic marker can be deﬁned as a characteristic associ-
ated with prognosis or outcome, usually in terms of relative hazard
of failure either time to recurrence/progression or death, whereas a
predictive marker is deﬁned as a characteristic that predicts the
differential efﬁcacy (beneﬁt) of a particular therapy based on mar-
ker status, that is, only patients with the marker will respond to the
speciﬁc treatment or will respond to a greater degree than individ-
uals without the marker [49]. Currently, the amount of ovarian tu-
mor remaining after cytoreduction in combination with patient
response to platinum drugs are the best factors to gauge ovarian
cancer patient prognosis [50,51]. That almost all epithelial ovarian
cancer patients receive chemotherapy means that it can be difﬁcult
to distinguish a marker for prognosis from a marker for prediction
of chemoresponse. An example of where the epigenetic basis for
the biology of tumor aggressiveness can be separated from re-
sponse to therapy is bladder cancer. A subset of superﬁcial bladder
tumors are cured after initial resection, others recur, while a
minority both recur and progress. Some of these superﬁcial bladder
tumors are not treated with chemotherapy and the role of epige-
netic alterations in the behavior of such tumors could be studied
to identify markers of prognosis.
4.2. Aberrant DNA methylation and prognosis
The methylation status of individual genes has been investi-
gated as a marker for prognosis of ovarian cancer. One study
looked at 235 ovarian cancer patients and found that the associa-
tion between hypermethylation of the IGFBP-3 gene and poor prog-
nosis was stronger in women with early stage disease [52]. In a
subsequent study, promoter methylation of IGFBP-3 in combina-
tion with CDKN2A, BRCA1 orMLH1was reported to increase the risk
of disease progression [53]. In another study, progression free sur-
vival of ovarian cancer patients was associated with hypomethyla-
tion of satellite DNA repeat sequences located on chromosome1
[54] and hypermethylation of 18S and 28S rDNA was also indica-
tive of progression free survival [55]. Determining a methylation
signature that predicts the amount of time until relapse and/or
overall survival would greatly impact individualized care regi-
mens. CpG island microarray analysis has identiﬁed additional can-
didate methylation markers of prognosis in ovarian cancer towards
the development of such signatures [56–58].
4.3. Histone modiﬁcations and prognosis
Histone core subunits share a common structure including an
extended tail that is the site of post-translation modiﬁcations.The most common modiﬁcations to histone tails include acetyla-
tion, methylation, phosphorylation and ubiquitylation. These mod-
iﬁcations have the ability to enhance or block transcription factor
binding and transcription initiation. As a result, dysregulated mod-
iﬁcations in the histone code can lead to aberrant gene expression
in tumor cells and likely contribute to the disease [1].
H3 histone can be methylated up to three times at K4, K9, K27,
K36 and K79. Trimethylation of H3K4 is linked to gene expression
while H3K27 trimethylation is associated with gene silencing. His-
tones are methylated at speciﬁc lysines and arginines by Histone
Methyl Transferases (HMTs). Two common HMTs are mixed line-
age leukemia (MLL) and Su(var)3-9, Enhancer of zeste, and tritho-
rax (SET1) [59]. Histones are demethylated by Histone
Demethylases (HDMs) including lysine speciﬁc demethylase 1
(LSD1) and jumonji AT-rich interactive domain 1 (JARIDI1) [60].
The availability of tumor tissue at time of surgery means that
histone modiﬁcations can be examined and any association with
prognosis studied. A particular pattern of histone marks is associ-
ated with hypermethylated CpG islands in promoters of genes in
tumor cells. For example, the repression of tight junction proteins,
claudin-3 and claudin-4, is reversed in ovarian cancer cell lines
through loss of H3K27me3 and H4K20me3 [61]. While this was
demonstrated in ovarian cancer cell lines, claudin-3 and claudin-
4 are consistently over-expressed in primary ovarian tumors and
claudin-3 over-expression is associated with poor prognosis, sup-
porting potential clinical relevance [62,63]. Additionally, the meth-
ylatransferase responsible for H3K27 methylation, Enhancer of
Zeste Homologue 2 (EZH2), is over-expressed in cells resistant to
cisplatin. Inhibition of EZH2 activity can resensitize ovarian cancer
cells to cisplatin treatment suggesting that histone methylation at
H3K27 plays a critical role in gene silencing [64].
4.4. MiRNA expression and prognosis
The expression levels of miRNAs as well as that of the enzyme
machinery for processing of miRNAs have been examined for asso-
ciation with prognosis of ovarian cancer. A study analyzing miRNA
expression proﬁles of 34 ovarian cancer tissues and 10 ovarian can-
cer cell lines found that miR-221 is the most consistently over-ex-
pressed miRNA in ovarian cancer [65]. In another study, when
ovarian carcinomas were compared to non-immortalized primary
ovarian surface epithelial cultures miR-221 was under-expressed
in ovarian carcinomas [66]. These conﬂicting results are likely
due to differences between the normal comparison samples but
supports the hypothesis that miR-221 is likely dysregulated in
ovarian cancer. MiR-221 along with miR-222 regulate cell cycle
progression and directly target CDK1B (p27) and CDK1C (p57)
[67,68]. The levels of both CDK1B and CDK1C are under-expressed
in ovarian cancer suggesting that miR-221 and miR-222 may be
playing a role in their mRNA transcript degradation. Mir-221 and
miR-222 are both transcribed on the X chromosome so their
expression levels are typically associated. Interestingly, ovarian
cancer patients with a worse overall survival had a lower ratio of
miR-221 to miR-222 [69].
While dysregulation of miRNAs is clearly involved in tumoro-
genesis [70], it is currently unclear how miRNAs are dysregulated
however incorrect processing of miRNA transcripts likely has a
role. In the nucleus, miRNA transcripts are processed into 70 nt
stem-loop pre-miRNA by the enzyme Drosha. Following this step
the pre-miRNA is transported into the cytoplasm where it is pro-
cessed by the enzyme Dicer into a 17–25 nt mature miRNA [71].
In a study of 111 epithelial ovarian cancers, Drosha expression
was decreased 51% and Dicer expression decreased by 60% com-
pared to benign ovarian epithelial tissue. In addition, decreased
Dicer expression correlated with advanced tumor stage and
decreased Drosha expression was associated with suboptimal
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a decrease in miRNA processing may affect the outcome of patients
with ovarian cancer. In support of these ﬁndings, a separate study
found that decreased Dicer expression in ovarian tumors was
correlated with lower patient survival time. MiRNA analysis of
the Dicer positive tumors versus Dicer negative patients indicated
that miRNA expression was lower in Dicer negative samples [73].
While it is possible that regulation of miRNA processing differs
between tissue types, other studies have conversely reported high
Dicer expression to be associated with poor prognosis in patients
with prostate and esophageal cancer [74,75].5. Prediction of response to therapy
5.1. Chemotherapy for ovarian cancer
Understanding and overcoming resistance to chemotherapy is
central to improving survival of cancer patients. The basis of che-
moresistance is multifactorial and is often thought of as intrinsic
or acquired. While mutation of individual genes such as RAS or
p53 can be relatively common in a tumor type, overall there is con-
siderable heterogeneity between the genetic, epigenetic and pre-
and post-translational alterations in the tumor cells of one patient
to another patient [76]. This is particularly true in high grade ser-
ous carcinomas, the most common and most lethal subtype of
ovarian cancer, and a tumor marked with signiﬁcant genomic
instability [77]. A very large collection of conventional chemother-
apy agents and a growing list of molecular targeted agents occa-
sionally provide signiﬁcant tumor cytoreduction and clinical
beneﬁt yet the selection of ‘best agents’ for a given individual’s tu-
mor is typically accomplished by trial and error. Women who are
diagnosed with ovarian cancer are given a platinum-based drug
therapy and those whose cancer progresses while on therapy or
who recur within 6 months are deemed platinum resistant. Only
at this time are the patients given alternative agents. Thus, it is
critical to identify biomarkers that can predict patient response
to platinum drugs so that optimal treatment can be administered
immediately.
The power of predictive biomarkers is now conﬁrmed in multi-
ple epithelial and mesenchymal tumors with examples including
the presence of Her-2-neu ampliﬁcation, c-Kit mutation, EGFR
mutations, or BCR-Abl rearrangement all of which have trans-
formed the treatment of certain subtypes of breast cancer, sar-
coma, lung cancer and leukemia, respectively [78–80]. Such
potent molecular based predictive biomarkers do not exist in epi-
thelial ovarian cancer with the possible exception of germline
mutations in BRCA genes which greatly increase the risk of subse-
quent serous carcinomas of the ovary and predict for response to
platinum [81,82] and poly(ADP-ribose) polymerase (PARP) inhibi-
tors [83]. Fig. 1B demonstrates potential approaches for women
diagnosed with ovarian cancer when predictive markers are avail-
able. Following diagnosis, a biopsy of the tumor is reviewed by a
pathologist and tumor cell DNA, RNA and/or protein are analysed
by global technologies to identify the patient’s time to recurrence,
overall survival as well as prediction of response to therapy based
on the molecular signature of the tumor.
In a recent paper, Boettcher and colleagues used microarray
technology to compare methylation proﬁles from doxorubicin sen-
sitive and resistant breast and ovarian cancer cell lines. Speciﬁcally
breast cancer cell line MCF-7_wt (doxorubicin sensitive) was com-
pared to MCF-7_ADR (a selected sub-line of MCF-7_wt that is
doxorubicin resistant). In addition, the methylation proﬁles of
ovarian cancer cell lines OVCAR-4 (inherently resistant), OVCAR-5
(sensitive) and NCI/ADR-RES (doxorubicin selected resistance)
were also compared. Hypermethylation of BRCA1, CDH1, DNAFC15and SULF2 and hypomethylation of ABC1, APC and HIC1 were ob-
served in doxorubicin resistant cell lines. Quantitative RT-PCR
was used to detect changes in gene expression which in most cases
was associated with methylation status of the corresponding gene
[84]. This study suggests that there are key hypomethylated or
hypermethylated genes involved in drug resistance which are po-
tential indicators of chemoresistance that could be used to deter-
mine appropriate therapy.
5.2. The BRCA/HR pathway and chemoresponse
The biological rationale for a better response to platinum or
PARP inhibitors in women with germline BRCA mutations or
‘‘BRCAness’’ is that the BRCA1 and BRCA2 genes are important for
double-strand break (DSB) repair by homologous recombination
(HR). Cells defective in BRCA1 or BRCA2 are more sensitive to cis-
platin and carboplatin, which cause covalent cross-links between
bases on the two opposite DNA strands termed interstrand DNA
cross-links. BRCA1 or BRCA2 negative cells show even greater
hypersensitivity to inhibition of the PARP enzyme that is involved
in base excision repair, a key pathway in the repair of DNA single
strand breaks. During S phase, it is believed that partially pro-
cessed cross-links cause stalling of the DNA replication machinery
and fork collapse. Base excision with incomplete repair can be con-
verted into DSB with progression of the DNA replication machin-
ery. These DSB would normally be repaired by HR in cells where
BRCA1 and BRCA2 are functional [85]. The impairment of base
excision repair is not lethal in cells with alternative mechanisms
of DNA repair but proves insurmountable in cells deﬁcient in HR,
such as is seen in tumors with loss of BRCA1 or BRCA2 function,
providing a therapeutic opportunity.
Epigenetic markers can also serve as predictive biomarkers,
with an example being the O6-methyl-guanine-DNA-methyltransfer-
ase (MGMT) gene, a DNA repair protein that removes mutagenic
and cytotoxic adducts from O6-guanine in DNA. The silencing of
the MGMT gene by the epigenetic mutation of hypermethylation
in gliomas is an independent predictor of a favorable response to
Temozolomide [86]. The epigenome of the cancer cell likely under-
lies at least a component of intrinsic and acquired chemoresistance
since some of the aberrant hypermethylation in the ovarian cancer
genome inactivates tumor suppressors which result in the loss of
function of key genes (such as BRCA1) or the impairment of key
pathways (such as BRCA/HR) [29,87].
5.3. BRCA1 and other HR gene methylation in cancer
The unexpected absence of inactivating point mutations of
BRCA1 in sporadic breast and ovarian cancers and the ﬁndings of
methylation as an alternative mechanism of inactivation of the
VHL, p16 andMLH1 classical tumor suppressor genes led to studies
of the methylation status of the BRCA1 promoter region in sporadic
breast and ovarian tumors reviewed in [88]. Several studies re-
ported that BRCA1 was hypermethylated in 10–15% of sporadic
ovarian tumors and that hypermethylation was strongly associated
with loss of expression at the RNA or protein level. It was also re-
ported that patients with hypermethylation of BRCA1 in ovarian tu-
mors had a better survival [88]. The subset of sporadic breast
tumors with BRCA1 methylation show a similar phenotype to
familial BRCA1 patient breast tumors termed ‘‘BRCAness’’ [88] Spo-
radic ovarian tumors with functional inactivation of BRCA1 by
hypermethylation will also have the BRCA deﬁciency phenocopy
[88]. The loss of BRCA1 expression caused by promoter hyperme-
thylation will disrupt BRCA-associated DNA repair and may sensi-
tize tumors to BRCA-directed therapies. The model for sensitivity
to PARP inhibition is dependent upon homologous recombination
deﬁciency rather than inherited BRCA mutation. Therefore PARP
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tional impairment of the HR pathway other than loss of BRCA1 or
BRCA2 [85]. The methylation, and thereby functional, status of
other genes implicated in the wider BRCA/HR pathway may also
be relevant to suitability of PARP inhibitor therapy.
The BRCA2 gene appears to be unmethylated in ovarian and
other cancers [89–91]. A Fanconi’s Anemia gene, FANC-F, was re-
ported to be frequently methylated in ovarian cancer and to be
associated with cisplatin resistance [92] but subsequent studies
have reported a lower frequency [28,93] and no association with
response to cisplatin [94]. The partner and localizer of BRCA2
(PALB2) gene [95] occasionally shows aberrant promoter hyperme-
thylation associated with loss of expression in sporadic ovarian tu-
mors mainly non-serous histologies. Ongoing genome-wide
studies e.g., The Cancer Genome Atlas (TCGA), should reveal the
methylation status of other BRCA/HR pathway genes in sporadic
ovarian cancer.
5.4. MiRNA and chemoresponse
MiRNAs have also been investigated as potential biomarkers of
chemoresistance [96]. To identify miRNAs that are dysregulated in
patients with resistance to platinum therapy, Eitan et al. (2009)
preformed microarray analysis of microRNA expression in patients
with stage III ovarian tumors sensitive to platinum-based therapies
compared to platinum-resistant patients. This study highlighted
several miRNAs that were differentially expressed at a signiﬁcant
level including miR-27a, miR-378 and miR-23a [97]. In another
study, decreased expression of let-7i was associated with shorter
progression-free survival identifying let-7i as a candidate marker
to detect patients who will recur sooner [98].
5.5. Epigenetics and radioresponse
Tumor cells can also be resistant to radiation therapy. For head
and neck cancer, radiation therapy is the standard adjuvant treat-
ment. Aberrant methylation of negative regulators of the Ras/PI3K/
AKT pathway has been investigated for association with outcome
after radiation therapy for oral cancer [99].
Cancer stem cells have the ability to progress through the cell
cycle to produce new tumor cells. It has been proposed that cancer
stem cells are responsible for cancer recurrence [100]. Cancer stem
cells, which by deﬁnition are epigenetic, have recently been shown
to be more resistant to chemotherapy than other cells in the tumor
and potentially more resistant to radiation therapy as well [101–
105].
The association of miRNA expression levels and response to
radiation therapy is an emerging area of research.
5.6. Recurrent ovarian tumors may have acquired additional
epigenetic alterations
The genotype of the cancer cell is dynamic. There is clonal selec-
tion for, and outgrowth of, a tumor cell with an acquired mutation
that confers a growth advantage over other tumor cells. While a
biopsy of a patient’s ovarian tumor obtained at initial diagnosis
is available to type for methylation status, it is possible that at
the time of recurrence after (ﬁrst line) therapy, the epigenome of
the dominant tumor cell clone has changed. A non-invasive analy-
sis of gene methylation in the recurrent tumor might allow better
stratiﬁcation of therapy options at time of recurrence (Fig. 1C). In
this regard, further development and testing of a blood-based as-
say for gene hypermethylation that we previously reported
[23,106] would be of interest.
Acquired resistance to platinum or PARP-inhibitors could arise
from a defect in methylation maintenance leading to globaldemethylation or, more likely, clonal outgrowth of cells in a tumor
that no longer have hypermethylation of BRCA1 for example. A sol-
itary study of BRCA1 in the literature found that the methylation
status (2 positive, 4 negative) was retained in 6 recurrent tumors
after interim chemotherapy [25].6. Epigenetic therapy
6.1. Demethylating agents
That epigenetic alterations are more plastic than genetic altera-
tions, the availability of epigenetic modulating drugs and that
these drugs have previously been used for cytotoxic therapy in
the clinic together have led to consideration and testing of epige-
netic therapy for cancer. The demethylating drugs azacitidine
and decitabine have been used as cytotoxic agents but demon-
strated limited efﬁcacy in clinical trials though with a likely
sub-optimal regimen. More recently, a strategy of a low dose of
azacytidine, better tolerated by patients, to increase sensitivity or
resensitize (delay or reverse resistance) to standard therapy has
been advocated [107–109]. The sensitivity would presumably
derive from reactivation of genes epigenetically silenced in the
tumor cells (but not surrounding normal tissue). Few genes have
been implicated in the chemoresponse of ovarian cancer, although
genes functioning in DNA damage response pathways are likely
candidates given themodeof action of platinum therapy. Pre-clinical
studies have examined the mismatch repair gene MLH1 and the
RASSF1A gene implicated in chemosensitivity by a putative role in
the control of microtubule stability [110,111].
Clinical trials testing efﬁcacy of demethylating agents exist for
several types of leukemia and exhibited promising results. These
studies are reviewed in [107]. In a phase 1b-2a clinical study, ovar-
ian cancer patients with resistance to carboplatinum therapy re-
ceived azacitidine and a partial reversal of platinum resistance
was reported [112]. A phase 1 trial to assess the ability of decita-
bine to reverse platinum sensitivity through global demethylation
found that after 8 days of treatment the HOX1A and BRCA1 genes
were unmethylated in plasma [113]. While there is no direct evi-
dence, it is conceivable that reactivation of tumor suppressor genes
with functions outside of DNA repair might also lead to growth
inhibition of tumor cells. As the ovarian cancer cell methylome is
further elucidated it should become clearer which key genes in
ovarian tumorigenesis are under epigenetic control and their bio-
logical function will provide a better rationale for the potential of
epigenetic therapy.
It has been argued that through the induction of genome-wide
hypomethylation, demethylating drug treatment could potentially
have detrimental effects for a cancer patient. For example, reacti-
vation of viral elements integrated into human DNA has been pos-
tulated although this may not be possible since the DNA sequence
will likely have accumulated mutation over millennia. The biolog-
ical effects of a twofold increase in gene dosage of imprinted genes
might not be a major issue as many imprinted genes code for pro-
teins with function in fetal development [114]. Global hypomethy-
lation has also been associated with chromosomal instability (CIN)
although it may already exist in the advanced stage ovarian tumor
that would potentially receive demethylating treatment. Another
issue is that, as discussed above, aberrant methylation of some
genes may confer an increased response to chemotherapy for
example, ovarian tumors with BRCA1, GSTP1 or MGMT methylation
[28]. Since the primary ovarian tumor biopsy would likely be avail-
able from surgery, ovarian cancer patients could be typed for
methylation of BRCA1, GSTP1 or MGMT or other ‘‘beneﬁcial’’ meth-
ylation and stratiﬁed for suitability to demethylating drug therapy.
Perhaps of more immediate relevance are the more practical issues
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rapid remethylation after the end of treatment [24,107].
6.2. Histone deacetylating agents
Acetylation and deacetylation of histones occurs by histone
acetylatransferases (HATs) and deacetylases (HDACs). Acetylation
of the lysine residue causes DNA to become more relaxed and tran-
scription factor binding competent. Conversely, deacetylation
compacts chromatin structure and results in gene silencing
[115,116]. Acetylation of H2A induces a conformational change of
the nucleosome and acts as a gene regulation switch [117]. Labora-
tory-based studies of HDAC inhibitors alone and in combination
with demethylating or other agents have demonstrated anti-tumor
effects and reactivation of cancer genes. Although, some genes can
be reactivated in cultured cells by treatment with an HDAC inhib-
itor alone e.g., p21, typically, histone deacetylation is involved with
DNA methylation for transcriptional regulation at gene promoters.
Clinical trials support a method of treating patients with combina-
tions of demethylation agents or DNMT inhibitors followed by or in
combination with HDAC inhibitors [118]. Experience with HDAC
inhibitors and ovarian cancer in the clinic is reviewed by [119].
6.3. MiRNA as targets of therapy
The deregulation of miRNA expression in tumor cells makes
miRNAs potential therapeutic targets [7,8,34,120,121]. Over-
expression of miRNAs that act as oncogenes can be targeted for
down-regulation by anti-miRNA oligonucleotides, miRNA masking,
miRNA sponges or small molecule inhibitors. Anti-miRNA oligonu-
cleotides are complementary sequences to miRNA and block the
miRNA’s ability to interact with its target mRNA transcript
[122,123]. The downside of this approach is that since an individ-
ual miRNA is involved in post-transcriptional control of many
different genes and pathways, there will likely be signiﬁcant off-
target effects. However, miRNA masking blocks the miRNA–mRNA
interaction through complementation but with more speciﬁcity
since the complement is to the mRNA of interest [124]. This ap-
proach depends on the ability to develop a sequence within the
miRNA binding site that is unique. A miRNA sponge contains sev-
eral binding sites and is capable of blocking many miRNAs at a
time [125]. Small molecule inhibitors of miRNAs are also being
investigated, such as azobenzene which was identiﬁed as a mir-
21 blocking agent [126]. MiRNA technology is being tested for efﬁ-
cacy in treating leukemia, prostate cancer, and skin cancer and
information on these clinical trials is reviewed in [127]. Restoring
the activity of tumor suppressor miRNAs can lead to inhibition of
tumor growth and apoptosis. Here miRNA mimics could be admin-
istered to restore miRNA activity. Several strategies for delivery of
RNAi therapeutics are under development [72,128].7. Conclusions
The plasticity, the identiﬁcation of epigenetic alterations in the
earliest known stages of cancer, and available sensitive technology
provide a compelling rationale for the utility of epigenetic altera-
tions for risk over lifetime and for early detection. The availability
of tumor tissue at time of biopsy or surgery allows for wider study
of epigenetic alterations and is not subject to the sampling issues
inherent to risk and early detection studies. Therefore, prognostic
indexes and prediction of response to therapy may have the most
immediate traction in translational epigenetic research. Epigenetic
alterations identiﬁed at time of biopsy could be used for monitor-
ing of tumor burden, screening for recurrence, and assessment of
efﬁcacy of therapy. Plasticity again, and the availability ofepigenetic modulating drugs have led to early studies of epigenetic
therapy.
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